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Introduction. Class 3 obesity (BMI ≥ 40 kg/m2) is a growing health problem worldwide associated with considerable comorbidity
including Type 2 diabetes mellitus (T2DM). The multidisciplinary medical management of obesity can be difficult in T2DM due
to potential weight gain from medications including sulphonylureas and insulin. However, newer weight-neutral/losing diabetes
medications can aid additional weight loss. The aim of this study was to compare weight loss outcomes of patients with
and without T2DM, and in patients with T2DM, to compare diabetes outcomes and change in medications at 6 months.
Methods. All patients entering a multidisciplinary weight management metabolic program in a publicly funded hospital
clinic in Sydney between March 2018 and March 2019, with BMI ≥ 40 kg/m2 and aged ≥18 years were included. Data was
collected from patient clinical and electronic notes at baseline and 6 months. Results. Of the 180 patients who entered the
program, 53.3% had T2DM at baseline. There was no difference in percentage weight loss in those with or without T2DM
(4:2 ± 4:9% vs. 3:6 ± 4:7%, p = 0:35). Additionally, T2DM patients benefited from a 0.47% reduction in HbA1c (p < 0:01)
and a reduction in the number of medications from baseline to 6 months (1:8 ± 1:0/patient vs. 1:0 ± 1:2/patient, p < 0:001).
T2DM patients who started on weigh-neutral/losing medications in the program lost more weight than those started on
weight-gaining medications (7:7 ± 5:3% vs. 2:4 ± 3:8%, p = 0:015). Conclusions. Patients with class 3 obesity had significant
weight loss at 6 months in this program. Patients with T2DM at baseline had comparable weight loss at 6 months, a significant
improvement in glycaemic control, and a reduction in diabetes medication load. Additionally, patients with T2DM who were
started on weight-neutral/losing medications lost significantly more weight than those started on weight-gaining medications,
and these medications should be preferentially used in class 3 obesity and comorbid T2DM.
1. Introduction
Obesity, defined as body mass index ðBMIÞ ≥ 30 kg/m2, is a
growing health problem with over a third of the global
population overweight or obese [1], and this is projected to
rise above 50% by 2030 [2]. Prevalence of class 3 obesity
(BMI ≥ 40 kg/m2) has risen precipitously by an estimated
76.5% from 2000 to 2012 [3] and is strongly associated with
increased mortality [4]. Obesity is associated with significant
medical comorbidity including type 2 diabetes mellitus
(T2DM), cardiovascular disease (CVD), obstructive sleep
apnoea (OSA), gastroesophageal reflux disease (GORD),
cancer, and arthritis [5, 6]. T2DM is highly prevalent in class
3 obesity with one study reporting 15.5% and 20.5% new
T2DM diagnoses in patients with a BMI of 40–49.9 kg/m2
and ≥50 kg/m2, respectively [7]. Complications of T2DM
make up a huge proportion of the economic burden of
comorbidity, as it has large economic effects across low
income as well as developed countries, and account for
1.8% of global GDP (projected to rise to up to 2.2% in
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2030) [8, 9]. Furthermore, complications of T2DM have
detrimental effects on health-related quality of life [10].
Class 3 obesity and T2DM are linked by several
pathophysiological mechanisms including insulin resistance,
inflammatory cytokines, altered lipid metabolism, and other
cellular processes [11]. T2DM and obesity confer additive
risk, as patients with T2DM are more likely to develop car-
diovascular disease (CVD) as their BMI increases [12]. Sim-
ilarly, amelioration of obesity and T2DM is closely linked,
as weight loss of 5-10% in T2DM has been shown to confer
a reduction of 0.6-1% in HbA1c and other metabolic benefits
[13]. Furthermore, results of the DiRECT trial using lifestyle
measures for T2DM showed a clear correlation between
weight loss and remission in recent onset T2DM, with 86%
remission in those who lost ≥15 kg at 1 year [14].
Bariatric surgery has been shown to be very effective for
weight loss in class 3 obesity with a significant number also
achieving T2DM remission [15]. However, bariatric surgery
services are limited and are currently unable to fully cater
for the scope of the obesity epidemic [16]. Furthermore,
determining fitness for surgery requires a complex, multidis-
ciplinary assessment with consideration of significant post-
operative demands [17]. Thus, many patients may opt for
nonsurgical weight loss programs including medical and life-
style management, even though weight loss outcomes are not
as impressive [18]. The Look AHEAD trial showed signifi-
cant weight loss of 6% in its intensive lifestyle arm at 9.6-
years median follow-up time [19], despite being stopped
prematurely due to no evidence of cardiovascular benefit
[20]. Multidisciplinary medical management including life-
style modification has also been shown to achieve short-
term weight loss and T2DM remission in severely obese pop-
ulations [21, 22]. Pharmacotherapy for obesity has been
shown to have modest efficacy ranging from 0.6 kg to 5.8 kg
in studies with short follow-up times (12–18 months)—how-
ever, these study populations were not restricted to class 3
obesity [23].
Physical activity is also an important aspect of the man-
agement of obesity and T2DM. Patients with T2DM who
performed at least moderate levels of physical activity have
been shown to have reduced all-cause mortality compared
to those who performed no or mild levels of physical activity
[24, 25]. Physical capacity outcomes have been shown to
improve in patients with class 3 obesity enrolled in our mul-
tidisciplinary program that included supervised exercise [26].
However, patients with class 3 obesity appear to face more
barriers to physical exercise than patients without class 3
obesity, and patients may decline participation in supervised
exercise programs [27].
The aim of pharmacotherapy in the treatment of T2DM
and comorbid class 3 obesity should be extended beyond gly-
caemic control to include weight management [28]. Unfortu-
nately, balancing glycaemic control and weight status can be
difficult. Many conventional diabetes medications used in
T2DM including sulphonylureas, pioglitazone, and insulin
can cause weight gain [28, 29]. Fortunately, the newer agents
of sodium-glucose transporter 2 (SGLT-2) inhibitors and
glucagon-like peptide-1 (GLP-1) agonists can promote
weight loss, while dipeptidyl peptidase-4 (DPP-4) inhibitors
are weight neutral [28, 29]. In a recent study, Aldekhail
et al. showed that class 3 obesity and T2DM patients in a
weight loss program prescribed weight-neutral/losing diabe-
tes medications lost more weight than those prescribed
weight-gaining medications [30].
In Australia, 31.3% of adults have obesity [31] and 3%
have class 3 obesity [32]. Access to bariatric surgery is very
limited in the public hospital system with >90% of surgeries
funded privately [16]. Lih et al. showed that a novel, multidis-
ciplinary metabolic rehabilitation program (MRP) model of
care can achieve greater weight loss and reduction in HbA1c
in class 3 obesity and T2DM than usual care in a diabetes
outpatient clinic [21]. Therefore, this exploratory observa-
tional study set out to evaluate the short-term outcomes of
weight loss and glycaemic control in a similar multidisciplin-
ary metabolic clinic that enrols patients with class 3 obesity
where the primary goal is to achieve weight loss.
Specifically, we aimed to answer the following research
questions:
(1) Does T2DM status at baseline influence weight loss at
6 months?
(2) For patients with T2DM at baseline, did glycaemic
control improve and did diabetes medication use
reduce at 6 months?
(3) For patients with T2DM at baseline, was diabetes
medication class associated with greater weight loss
at 6 months?
2. Materials and Methods
This study was conducted in a publicly funded, hospital-
based, multidisciplinary metabolic clinic in greater Sydney.
All patients enrolled were over 18 years of age with a BMI
≥40 kg/m2 and at least one weight-related medical comorbid-
ity, the most common being T2DM or nonalcoholic fatty
liver disease (NAFLD). The components of the metabolic
clinic have been previously described in detail by Atlantis
et al. [26]. In brief, the program offers a multidisciplinary
approach involving endocrinologists, a gastroenterologist,
dietitian, a psychiatrist, psychologists, physiotherapists and
a specialist nurse. Each patient attends two group education
sessions prior to attending their first medical appointment
with their physician. All patients are seen by a psychologist
and a dietitian, and those with diabetes see a diabetes educa-
tor (specialist nurse). Then, depending on clinical need and
availability, patients are reviewed every 6–12 weeks. Notably,
the use of pharmacotherapy for obesity is very limited within
the metabolic program, as none of the agents are subsidised
by the Pharmaceutical Benefits Scheme (PBS) in Australia.
In addition, all patients are offered the opportunity to attend
on-site group exercise classes supervised by a physiothera-
pist. Patients were encouraged to attend at least 3 sessions
per week and could attend more if desired. Around half of
the patients in the program opt to attend the exercise classes.
All patients first seen in the program between March 2018
and March 2019 that attended at least one medical appoint-
ment were included in this study. Exercise participation was
2 Journal of Diabetes Research
recorded if patients attended three or more classes during the
6-month follow-up period. Detailed history and blood tests
were collected at baseline and 6 months for all patients as part
of routine care. Patients who were included at baseline were
followed up between 4 and 8months with the aim of recording
data closest to the 6-month follow-up time. Electronic and
paper records were reviewed to obtain demographic details
and medical history including anthropometry, medications,
and blood results.
Diabetes medication prescribing was classed as weight-
neutral/losing and weight-gaining as previously described
in Aldekhail et al. [30]. The weight-neutral/losing class was
composed of patients on metformin only or metformin
combined with a SGLT-2 inhibitor, a DPP-4 inhibitor, or
a GLP-1 agonist. The weight-gaining medication class
was composed of patients on a sulphonylurea, pioglita-
zone, or any combination of medications including insulin.
Patients prescribed a combination of two classes were con-
sidered to be in a mixed-weight-effect class. The term
“baseline diabetes medications” signifies the medications
that patients were prescribed before entering the multidisci-
plinary clinic. However, this study focussed on comparing
the differences in outcomes at 6 months for those who were
started on the weight-gaining class of diabetes medications
during their time in the program versus patients who were
started on the weight-neutral/losing class of medications.
The study was approved by the South West Sydney Local
Health District (SWSLHD) Quality Improvement Commit-
tee (Reference: CT22_2018) as approved by the SWSLHD
Health Research Ethics Committee.
2.1. Data Analysis. The results were reported as the percent-
ages and mean ± standard deviations. Differences in baseline
characteristics between groups were evaluated for patients
completing 6-month follow-up, using independent samples
t-test for continuous variables and Pearson’s chi-square test
for categorical variables. Weight loss was converted into the
percentage of body weight loss. Weight loss at 6 months
was evaluated with paired t-tests for T2DM and non-
T2DM patients. The comparison of mean percent weight loss
and the proportion that lost ≥5% body weight between
T2DM and non-T2DM patients was performed using inde-
pendent samples t-testing and Pearson’s chi-square testing,
respectively. For patients with T2DM at baseline only, paired
samples t-tests and McNemar tests were used to assess
change in continuous and categorical variables, respectively,
over 6 months. Independent samples t-testing was conducted
to assess difference in mean percentage weight loss and
changes to diabetes medication class prescribing. P < 0:05
was considered statistically significant. All statistical analyses
were performed with SPSS version 26.
3. Results
A total of 180 patients attended at least one medical appoint-
ment from March 2018 to March 2019, with 82% attending
follow-up at 6 months as shown in Figure 1. Blood test results
were available for 92% of patients who attended at baseline.
There was no statistical difference between the proportion
of patients lost to follow-up in patients with or without
T2DM at baseline (13.5% vs. 23.3%, p = 0:08) as seen in
Figure 1. Patients who were lost to follow-up were younger
(mean age 44:1 ± 15 years vs. 51:0 ± 13:6 years, p = 0:01)
and had less hypertension (45.5% vs. 69.4%, p < 0:01), less
dyslipidaemia (45.5% vs. 65.3%, p = 0:03), and a history of
fewer cardiac events at baseline (0 vs. 20.4%) compared
to the baseline characteristics of those who were reviewed
at 6 months.
Among patients who completed 6-month follow-up, at
baseline, patients with T2DM weighed significantly less
(137:4 ± 25:1 vs. 148:8 ± 37:8 kg, p = 0:038) but had no dif-
ference in BMI (50:0 ± 7:4 vs. 53:0 ± 11:0 kg/m2, p = 0:07).
Patients with T2DM also had more diagnoses of hyperten-
sion (78.3% vs. 57.8%, p < 0:01) and dyslipidaemia (80.7%
vs. 45.3%, p < 0:001). There were no other significant differ-
ences in the presence of comorbidities in T2DM patients
compared with non-T2DM patients as shown in Table 1.
The mean duration of T2DM was 9:8 ± 8:1 years. Approxi-
mately one-third of patients (31.3%) with T2DM had
microvascular complications, and 19.3% had evidence of
macrovascular complications at baseline. Serum cholesterol
(4:2 ± 1:1 vs. 4:6 ± 1:0mmol/L, p < 0:05) and LDL choles-
terol (2:1 ± 1:0 vs. 2:7 ± 0:9mmol/L, p < 0:001) were lower
in the T2DM group, while triglycerides were higher in the
180 patients who attended at least one medical
appointment
13 patients with T2DM and 20
patients without T2DM at
baseline lost to follow-up at 6






T2DM at 6 months
64 patients without
T2DM at 6 months
Figure 1: Entry of patients at baseline and loss to follow-up at 6 months, by T2DM status.
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non-T2DM group (2:3 ± 1:4 vs. 1:5 ± 0:7mmol/L, p < 0:001).
There was similar participation in the supervised exercise
program between the patient groups with and without
T2DM (50.6% vs. 60.9%, p = 0:3).
At 6-month follow-up, there was significant weight loss
in both patients with T2DM (5:8 ± 6:8 kg, p < 0:001) and
without T2DM (5:3 ± 7 kg, p < 0:001). There was no statis-
tically significant difference in the mean percentage weight
loss between patients with or without T2DM (4:2 ± 4:9%
vs. 3:6 ± 4:7%, p = 0:35), as shown in Figure 2(a). There
was also no difference between groups in the proportion
of patients who lost ≥5% body weight (42.2% vs. 34.4%,
p = 0:18) at 6 months as shown in Figure 2(b). There was
no difference in the proportion of patients who lost ≥10%
weight loss at 6 months in the T2DM and non-T2DM groups
(10.8% vs. 6.3%, p = 0:33). The follow-up duration at the time
of data extraction between patients with T2DM and without
T2DM was similar (6:3 ± 0:9 vs. 6:2 ± 0:7 months, p = 0:24).
Table 1: Baseline characteristics of patients that were followed up at 6 months, by T2DM status at baseline.
Variable (mean ± SD or %) T2DM
(n = 83) Without T2DM (n = 64) P value
Age (years) 52:8 ± 13:2 48:7 ± 13:7 0.068
Females (%) 73.5 67.2 0.41
Caucasian ethnicity (%) 72.3 75.0 0.71
Weight (kg) 137:4 ± 25:1 148:8 ± 37:8 0.038
BMI (kg/m2) 50:0 ± 7:4 53:0 ± 11:0 0.066
Previous bariatric surgery (%) 4.2 9.5 0.27
In paid employment (%) 31.3 26.6 0.53
Exercise class participation (%) 50.6 60.9 0.21
Hypertension (%) 78.3 57.8 <0.01
Dyslipidaemia (%) 80.7 45.3 <0.001
CKD grade 3 or below (%) 15.2 13.6 0.79
Cardiovascular disease (%) 24.1 15.6 0.21
Fatty liver disease (%) 72.3 78.1 0.42
Obstructive sleep apnoea (%) 50.6 46.9 0.65
Gastroesophageal reflux disease (%) 47.0 46.0 0.91
Cholesterol (mmol/L) 4:2 ± 1:1 4:6 ± 1:0 0.038
Triglycerides (mmol/L) 2:3 ± 1:4 1:5 ± 0:7 <0.001
HDL (mmol/L) 1:1 ± 0:3 1:2 ± 0:3 0.46
LDL (mmol/L) 2:1 ± 1:0 2:7 ± 0:9 0.002











































Figure 2: (a) Mean percent weight loss at 6 months by T2DM status at baseline (p = 0:35), (T2DM, n = 83; non-T2DM, n = 64). (b) Weight
loss of ≥5% body weight at 6 months by T2DM status at baseline (p = 0:18), (T2DM, n = 83; non-T2DM, n = 64).
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Patients with T2DM achieved a mean HbA1c reduction
of 0.47% (p < 0:01) at 6 months, with a significantly higher
proportion achieving HbA1c < 6:5% at 6 months compared
to baseline (31.6% vs. 19.7%, p < 0:05) as shown in Table 2.
At 6 months, 8.4% of patients were off all diabetes medica-
tions and had anHbA1c < 6:5%. There was an overall reduc-
tion in the number of diabetes medications from baseline to 6
months (1:8 ± 1:0/patient vs. 1:0 ± 1:2/patient, p < 0:001).
More patients were treated with lifestyle measures alone at
6 months compared to baseline (50.6% vs. 8.4%, p < 0:001),
and fewer patients were treated with two or more agents
(61.4% vs. 30.1%, p < 0:001) at 6 months. Fewer patients were
treated with metformin or a sulphonylurea, and patients who
required insulin were treated with fewer units (total daily
dose) at 6 months compared with baseline (138:4 ± 96:1 vs.
82:3 ± 47:5, p < 0:05).
There was a statistically significant reduction in pre-
scribing of weight-neutral/losing diabetes medications at
6 months (43.4% vs. 24.1, p = 0:024), while reduction in
prescribing of weight-gaining diabetes medications (34.9%
vs. 21.7%, p = 0:071) and mixed-effect medications (13.6%
vs. 3.6%, p = 0:057) approached significance at 6 months.
Patients with T2DM who were changed onto weight-
neutral/losing diabetes medications during the program lost
more percent body weight than those changed onto weight-
gaining medications during the program (7:7 ± 5:3% vs.
2:4 ± 3:8%, p = 0:02) as shown in Figure 3.
4. Discussion
These results from a real-world multidisciplinary weight
management program demonstrate that significant weight
loss, improved glycaemic control, and reduced medication
load are possible in adults with class 3 obesity and T2DM
at 6 months. Weight loss was achieved despite our cohort
having a significantly greater burden of comorbidities com-
pared to Australian Bariatric Surgery Registry data, including
a higher prevalence of T2DM (54.6% vs. 13.6%) and higher
BMI (51:3 ± 9:1 kg/m2 vs. 41.8 kg/m2) [33]. The mean BMI
of our cohort (51:3 ± 9:1 kg/m2) is also significantly higher
than pooled patient data from international systematic
reviews of lifestyle interventions (37.1 kg/m2) and bariatric
surgery (45.62 kg/m2) in obesity [15, 18]. The finding that
older patients with more hypertension and a history of
cardiovascular events were less likely to stop attending the
program at 6 months may represent a greater perceived
importance of the clinic by patients with greater health needs.
Our cohort’s higher BMI and increased comorbidity levels
likely reflect higher patient selectivity by publicly funded
programs due to lack of resources and patient access to
multidisciplinary metabolic weight management clinics in
Australia [34].
Patients with T2DMwere older and had more comorbid-
ities at baseline despite having more favourable cholesterol
profiles, which was likely due to more lipid-lowering agent
Table 2: Glycaemic control and diabetes medications at 6 months, for patients who had T2DM at baseline.
Variable (mean ± SD or %) Baseline (n = 83) 6 months (n = 64) P value
HbA1c (n = 76)
HbA1c (%) 7:7 ± 1:7 7:3 ± 1:3 0.003
HbA1c (mmol/mol) 61:4 ± 18:5 55:7 ± 13:7
Percentage with HbA1c < 6:5% 19.7 31.6 0.035
Number of diabetes medications per patient 1:8 ± 1:0 1:0 ± 1:2 <0.001
Type of therapy (%)
Lifestyle only 8.4 50.6 <0.001
Monotherapy 30.1 19.3 0.18
≥2 medications 61.4 30.1 <0.001
Type of medication (%)
Metformin 79.5 43.4 <0.001
Sulphonylurea 18.1 6.0 0.03
DPP-4 inhibitors 14.5 7.2 0.18
GLP-1 analogues 10.8 7.2 0.61
SGLT-2 inhibitors 26.5 14.5 0.087
Acarbose 1.0 0.0 N/A
Insulin 33.7 20.5 0.061
Insulin total daily dose (units) 138:4 ± 96:1 82:3 ± 47:5 0.014
Prescribing pattern (%)
Weight-neutral/losing 43.4 24.1 0.024
Weight-gaining 34.9 21.7 0.071
Mixed-effect 13.3 3.6 0.057
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use seen in the T2DM patients. Despite these baseline differ-
ences, patients with T2DM achieved similar weight loss
(4:2 ± 4:9 vs. 3:6 ± 4:7% body weight, p = 0:35) at 6 months.
This finding that T2DM did not affect weight loss, in spite
of a mean diabetes duration of almost 10 years, is encourag-
ing and consistent with cohorts in an intensive medical pro-
gram [22] and postbariatric surgery [35]. However, these
findings conflict with earlier studies where T2DM patients
fared worse after bariatric surgery [36] and in a behavioural
weight-control program [37]. Anderson et al. proposed
several barriers that may explain differences in weight loss
for T2DM patients including genetic or metabolic predispo-
sition to obesity, fear of hypoglycaemia, diabetes medica-
tions, weight-gaining medications used in the management
of diabetes-related complications, and limitations placed on
physical activity [38]. When compared to a similar metabolic
rehabilitation program, patients with T2DM had comparable
weight loss [21].
Specific weight goals were not recommended across the
clinic, but patients agreed on realistic and achievable indivi-
dualised weight goals with the clinical team. Modest weight
loss was able to be achieved alongside improved glycaemic
control and reduction in diabetes medication load in adults
with T2DM. Furthermore, 8.4% of patients achieved an
HbA1c of <6.5% while off diabetes medications at 6 months.
These patients may achieve diabetes remission if they main-
tain this at longer-term follow-up. Our study findings are
similar to the Look AHEAD trial that demonstrated that sig-
nificant weight loss in T2DM (5-10%) was associated with
improved glycaemic control, diabetes remission, lowered dia-
betes medication load, and improved fitness [19, 39, 40]. The
DiRECT trial also showed that with a weight loss of 8.8 kg,
patients achieved a 0.85% reduction in HbA1c, diabetes
remission in 46% and a 0.8 mean reduction in diabetes med-
ications at 12 months [14]. Despite achieving more modest
weight loss (4:2 ± 4:9% for T2DM patients) in this study, it
is reassuring that T2DM patients did achieve comparable
reductions in HbA1c and diabetes medication load. Addi-
tionally, the HbA1c reduction of 0.47% achieved in our study
is in line with results achieved by the real-world use of
weight-neutral/losing medications in diabetes clinics over
12 months [41]. Furthermore, any reduction in HbA1c in
overweight patients has been shown in many studies, includ-
ing the UK Prospective Diabetes Study (UKPDS), to reduce
long-term diabetes complications (particularly microvascu-
lar), diabetes-related death, and all-cause mortality [42]. It
is therefore reassuring that the HbA1c reduction in our
cohort to 7:3 ± 1:3% is likely to confer those benefits if sus-
tained over time.
This study adds more support for prescribing weight-
neutral/losing diabetes medications to patients with class 3
obesity in medical programs for weight loss. Aldekhail
et al. showed that patients with T2DM prescribed a
weight-neutral/losing medication lost more weight than
those prescribed weight-gaining medication [30]. Our study
supports this finding although we showed that changing to
weight-neutral/losing medications during the program was
associated with more weight loss than changing to weight-
gaining medications. Reductions in medication load would
be welcome for any patient with a long-term condition,
and the reduction in sulphonylurea use and total daily
dose of insulin is likely to lead to reduction in hypoglycae-
mia risk and incidence. However, there was no statistical
difference in the use of weight-neutral/losing and -gaining
7.7
2.4




















Changed onto weight losing/neutral medication(s) (n = 11)
Changed onto weight gaining medication(s) (n = 10)
Figure 3: Change to diabetes medication class and weight loss at 6 months for T2DM patients.
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medications at baseline compared to 6 months (24.1% vs.
21.7%). This finding likely represents a missed opportunity
of pharmacotherapy-aided weight loss with newer agents in
patients with T2DM. When added to metformin monother-
apy, GLP-1 agonists have been shown to induce modest
weight loss while DPP-4 inhibitors appear weight neutral
across a large meta-analysis of RCTs [43]. SGLT-2 inhibitors
have also been shown to induce weight loss compared to
placebo across several meta-analyses [44], and additionally
reduce cardiovascular events in patients with preexisting ath-
erosclerotic disease [45, 46]. Guidelines updated in 2018 by
the American Diabetes Association (ADA) and European
Association for the Study of Diabetes (EASD) give clinicians
scope to choose from several agents to combine with metfor-
min monotherapy, and highlight weight as an important
patient factor in decision-making [47]. Our findings are con-
sistent with this message that, upon entry into a medical
weight loss program, consideration should be given to the
use of weight-neutral/losing diabetes medications in prefer-
ence to weight-gaining medications, although cost, duration
of diabetes, cardiovascular risk, and baseline HbA1c may
affect choice of medication.
The finding that patients with T2DM achieved similar
rates of exercise participation to patients without T2DM is
encouraging, as patients with T2DM are less likely to meet
national recommendations for physical activity [48], and
may be impeded by autonomic/peripheral neuropathy and
other disabilities [49]. Furthermore, our group has previously
evaluated physical capacity outcomes in our clinic at 12
months and found improvements in several outcomes
including the 6-minute walk test, which has been shown to
be important for the quality of life in other disease popula-
tions [50]. Regular moderate levels of physical activity have
been shown to reduce mortality in T2DM patients [24, 25],
and further studies could investigate the cardiovascular
benefits of exercise in class 3 obesity and comorbid T2DM.
The main strength of this study is that it was conducted
in a real-world clinic that included all patients enrolled in a
publicly funded hospital service with class 3 obesity and com-
plex medical comorbidities. This could be replicated in other
clinics and centres which manage patients with class 3 obe-
sity and complex medical problems, in contrast to many clin-
ical trials that have strict inclusion and exclusion criteria, and
often exclude patients with complex medical conditions. This
study was also able to access detailed clinical data and pathol-
ogy, including diabetes medications prescribed. Limitations
of this study include the unrecorded duration of diabetes
medications taken before joining the clinic, its retrospective
design, short follow-up time of 6 months, and attrition of
18.3% at 6 months, although this rate of attrition is often seen
in a real-world clinic.
5. Conclusions
Patients with class 3 obesity and T2DM at baseline achieved
similar weight loss and exercise participation to those with-
out T2DM. In addition, patients with T2DM benefited from
improved glycaemia and reduction of diabetic medication
load at 6 months. These benefits support the multidisciplin-
ary model of care for patients with class 3 obesity that is cur-
rently recommended in Australia [34]. Patients started on
weight-neutral/losing diabetes medications lost more weight
than those started on weight-gaining diabetes medications.
Studies with longer follow-up are needed to further evaluate
weight loss and glycaemic control according to diabetes
medication use in class 3 obesity and comorbid T2DM.
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